home / stock / ubx / ubx news


UBX News and Press, Unity Biotechnology Inc. From 12/13/21

Stock Information

Company Name: Unity Biotechnology Inc.
Stock Symbol: UBX
Market: NASDAQ
Website: unitybiotechnology.com

Menu

UBX UBX Quote UBX Short UBX News UBX Articles UBX Message Board
Get UBX Alerts

News, Short Squeeze, Breakout and More Instantly...

UBX - Nasdaq Biotechnology rejig: VTRS, NVCR among added, KALA, VYNE among deleted

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

UBX - ARWR, CRDF and ORTX among pre market gainers

Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...

UBX - Unity Biotechnology posts biggest intraday gain after Q3 earnings

With the biggest ever intraday gain, Unity Biotechnology (UBX +30.0%) is trading near a two-month high after the company reported its Q3 2021 financials and provided business updates. The highlights of the earnings release include upcoming milestones from biotech’s clinical studie...

UBX - BGFV, BEKE and IMMP among pre market gainers

RenovoRx (NASDAQ:RNXT) +68% after presentation on treatment platform RingCentral (NYSE:RNG) +26% after boosting full-year revenue outlook; buys Mitel's IP rights and patents Valneva SE American Depositary (NASDAQ:VALN) +25% on European nod to procure up to 60M do...

UBX - Unity Biotechnology EPS beats by $0.09

Unity Biotechnology (NASDAQ:UBX): Q3 GAAP EPS of -$0.30 beats by $0.09. Cash, cash equivalents, and marketable securities totaled of $88.5M Press Release For further details see: Unity Biotechnology EPS beats by $0.09

UBX - UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates

UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22 UNITY to present at invitation-only Eyecelerator innovation conference at AAO SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (U...

UBX - UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection Patients with wet age-related macular degeneration showed improvement in visual acuity through 1...

UBX - Aditxt, Synaptogenix leads healthcare gainers; UpHealth, Unity Biotechnology among major losers

Gainers: Aditxt (NASDAQ:ADTX) +22%, Synaptogenix (NASDAQ:SNPX) +17%, Shineco (NASDAQ:TYHT) +13%, SmileDirectClub (NASDAQ:SDC) +12%, Silverback Therapeutics (NASDAQ:SBTX) +9%. Losers: UpHealth (NYSE:UPH) -34%, Unity Biotechnology (NASDAQ:UBX)&#...

UBX - Stocks Moving in the premarket session (OCGN, ENVB, SNPX, UBX, NERV, BLBX)

Futures are up over 0.4% in the pre-market sessions and it looks like it will be a bull’s day today. Futures on the Dow Jones Industrial Average gained 151 points, or 0.47%. S&P 500 futures rose 0.44% while Nasdaq 100 futures added 0.4%. Treasury Secretary Janet Yellen cautioned Tu...

UBX - UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease

Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of senolytic therapeutic approach; data builds on previously reported results at 8 weeks...

Previous 10 Next 10